Session » Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

Date: Sunday, November 8, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1126

A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study

9:00AM-11:00AM: Abstract Number: 1137

Access to Digital Health in an Urban Rheumatology Population

9:00AM-11:00AM: Abstract Number: 1127

Association of Health Literacy and Numeracy with Patient Reported Psychological Outcomes

9:00AM-11:00AM: Abstract Number: 1135

Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1144

Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic

9:00AM-11:00AM: Abstract Number: 1147

Development of a Digital Toolkit to Improve Quality of Life of Patients with Systemic Lupus Erythematosus: A Pilot Study

9:00AM-11:00AM: Abstract Number: 1129

Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis

9:00AM-11:00AM: Abstract Number: 1138

Estimation of Clinically Important Differences in Patient-Reported Outcomes Measurement Information System (PROMIS) Measures in Juvenile Myositis

9:00AM-11:00AM: Abstract Number: 1140

How Did SARS-CoV2/COVID-19 Pandemic Affected Patients with Rheumatic Diseases in Latin America? A Regional Survey from PANLAR

9:00AM-11:00AM: Abstract Number: 1142

Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution

9:00AM-11:00AM: Abstract Number: 1145

Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1133

Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies

9:00AM-11:00AM: Abstract Number: 1131

Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model

9:00AM-11:00AM: Abstract Number: 1130

Patient Perspectives on Biobanking and Data-linkage for Rheumatic Disease Research

9:00AM-11:00AM: Abstract Number: 1125

Patient Reported Impact of Lupus on Quality of Life

9:00AM-11:00AM: Abstract Number: 1146

Pilot Study of an Internet-Based Pain Coping Skills Training Program for Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1134

Prevalence of Frailty and Associated Factors in a National Observational Cohort of Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1139

Primary Non-adherence in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1132

Reliability of Virtual Sources of Education for Patients with Vasculitis

9:00AM-11:00AM: Abstract Number: 1141

Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by Chinese New Year and COVID-19 Epidemic via Online Interaction with SSDM

9:00AM-11:00AM: Abstract Number: 1136

Survey of Medical Cannabis Use in Lupus and Scleroderma

9:00AM-11:00AM: Abstract Number: 1128

The Diagnosis of Systemic Sclerosis as a Traumatic Experience: Patients’ Reactions to the Diagnostic Process

9:00AM-11:00AM: Abstract Number: 1143

The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].